Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Meng on MRI-US Fusion Targeted Biopsy for High-Grade Prostate Cancer

July 24th 2015

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Dr. Karsh on the TERRAIN Trial for Prostate Cancer

July 13th 2015

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Sequencing Strategies for Radium-223: Still in Its Nascence?

July 6th 2015

Neal Shore, MD, recently visited the OncLive News Network studios to discuss his role in LUGPA and provide his clinical insights about skeletal complications and the sequencing of radium-223.

Radium-223 Focus of Several Ongoing Combination Studies in mCRPC

June 30th 2015

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.

A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

June 28th 2015

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Fluoride PET/CT Scan Could Guide Treatment Selection in Bone Metastatic CRPC

June 26th 2015

Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.

Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

June 23rd 2015

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer Prevention

June 18th 2015

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Performance Status in Progressive mCRPC

June 11th 2015

Case Study: Symptomatic, Progressing mCRPC

June 11th 2015

Sequential and Combined Therapies in mCRPC

June 11th 2015

Case Study: Newly Diagnosed Metastatic Prostate Cancer

June 11th 2015

Importance of Detecting Early Metastasis in CRPC

June 11th 2015

Case Study: Newly Diagnosed High-Risk Prostate Cancer

June 11th 2015

Initiation and Reintroduction of Docetaxel in Prostate Cancer

June 11th 2015

Role of Docetaxel in Newly Diagnosed Prostate Cancer

June 11th 2015

Case Study: Treating High Risk CRPC

June 11th 2015

Introduction: Review of CRPC Guideline Updates

June 11th 2015

Abiraterone Delays Time to First Opiate Use in mCRPC

June 5th 2015

Clinical Trials for Non-Metastatic CRPC

June 5th 2015